Biotech BMTC GROUP INC. ANNOUNCES FINANCIAL RESULTS FOR THE QUARTER ENDED APRIL 30th, 2022. July 1, 2022
Biotech Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability July 1, 2022
Biotech Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule July 1, 2022
Biotech Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis June 21, 2022